Sign In
Buy SNGX
$0.362
-0.0003 (-0.0829%)
At Close: Jul 28, 2026
Short Interest in Soligenix Inc. (NASDAQ:SNGX) Decreases By 12.5%
01:20am, Thursday, 05'th Feb 2026
Soligenix Inc. (NASDAQ: SNGX - Get Free Report) was the target of a significant drop in short interest in the month of January. As of January 15th, there was short interest totaling 454,993 shares, a
Positive Clinical Results from Phase 2 Trial of SGX945 for the Treatment of Behçet's Disease Published in Rheumatology (Oxford)
07:30am, Thursday, 18'th Dec 2025
Study results support advancing SGX945 in this difficult-to-treat orphan disease Results suggest potential durability of response for maintenance therapy PRINCETON, N.J. , Dec. 18, 2025 /PRNewswire/ -
Soligenix Psoriasis Trial Extension Shows Better Outcomes With New Gel
01:23pm, Wednesday, 17'th Dec 2025
Soligenix, Inc. (NASDAQ: SNGX) on Wednesday announced extended results of its ongoing Phase 2a trial of SGX302 (synthetic hypericin) for mild-to-moderate psoriasis.
Soligenix Announces Top-line Results of the Phase 2a Study of SGX302 (Synthetic Hypericin) in Patients with Mild-to-Moderate Psoriasis
07:30am, Wednesday, 17'th Dec 2025
Optimized Gel Formulation Demonstrates Clinical Success in Third Cohort of Patients PRINCETON, N.J. , Dec. 17, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-st
Soligenix Inc. (NASDAQ: SNGX) Innovative Platform Provides Novel Treatment for Underserved CTCL Space
08:30am, Wednesday, 03'rd Dec 2025
NEW YORK, Dec. 03, 2025 (GLOBE NEWSWIRE) -- via BioMedWire: — Soligenix Inc. (NASDAQ: SNGX) today announces its placement in an editorial published by BioMedWire ("BMW"), one of 75+ brands within t
50 of 80 patients enrolled in FLASH 2 study Blinded Response Rate to Date Exceeds Trial Estimate PRINCETON, N.J. , Nov. 19, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Co
Soligenix Announces Recent Accomplishments and Third Quarter 2025 Financial Results
07:30am, Friday, 07'th Nov 2025
PRINCETON, N.J. , Nov. 7, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to
Soligenix Updates United States Medical Advisory Board for Cutaneous T-Cell Lymphoma
07:30am, Tuesday, 14'th Oct 2025
Providing Strategic Medical Guidance in Advancing HyBryte™ Clinical Development PRINCETON, N.J. , Oct. 14, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stag
FLASH 2 Study Interim Efficacy Analysis Targeted for 1H2026 Enrollment Update Remains on Track for 4Q2025 PRINCETON, N.J. , Oct. 7, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or th
Soligenix Announces Expansion of European Medical Advisory Board for Cutaneous T-Cell Lymphoma
07:30am, Tuesday, 30'th Sep 2025
In preparation for health authority interactions in pursuit of marketing approvals in Europe PRINCETON, N.J. , Sept. 30, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Comp
Soligenix Announces Closing of $7.5 Million Public Offering
04:05pm, Monday, 29'th Sep 2025
Cash runway extended through 2026 to fund multiple expected key inflection points PRINCETON, N.J. , Sept. 29, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) ("Soligenix" or the "Company"), a l
Soligenix Announces Pricing of $7.5 Million Public Offering
06:33am, Friday, 26'th Sep 2025
PRINCETON, N.J. , Sept. 26, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) ("Soligenix" or the "Company"), a late-stage biopharmaceutical company focused on developing and commercializing product
Soligenix Announces Appointment of Former White House Economic Adviser Tomas J. Philipson, PhD as Strategic Advisor
07:30am, Tuesday, 23'rd Sep 2025
Contributing Broad Business and Government Affairs Expertise and Network PRINCETON, N.J. , Sept. 23, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopha
Two Year Stability demonstrated in both bivalent and trivalent configurations at temperatures of 40°C / 104°F PRINCETON, N.J. , Sept. 4, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligeni
Soligenix Invited to Present at the H.C. Wainwright 27th Annual Global Investment Conference
07:30am, Tuesday, 02'nd Sep 2025
PRINCETON, N.J. , Sept. 2, 2025 /PRNewswire/ -- Soligenix, Inc. (Nasdaq: SNGX) (Soligenix or the Company), a late-stage biopharmaceutical company focused on developing and commercializing products to
